Bebifrin drops 0.125%, 10ml
Expiration Date: 05/2027
Russian Pharmacy name:
Бебифрин капли 0,125%, 10мл
Intranasally.
For children aged 4 to 6 years - 1-2 doses in each nasal passage, no more than every 6 hours; from 6 to 12 years old - 2-3 doses in each nasal passage, no more than every 4 hours. The duration of treatment without consulting a doctor is no more than 3-5 days. Use the drug only according to the indications, the route of administration and the doses indicated in the instructions.
Nasal drops in the form of a clear, colorless or weakly colored liquid.
1 ml phenylephrine hydrochloride 1.25 mg
Excipients: benzalkonium chloride - 0.18 mg, anhydrous glycerol - 50 mg, macrogol 1500 (polyethylene glycol 1500) - 15 mg, sodium hydrogen phosphate dihydrate - 2.26 mg, potassium dihydrogen phosphate - 1.01 mg, disodium edetate dihydrate (Trilon B) - 0.2 mg, water d / i - up to 1 ml.
Arterial hypertension,
severe atherosclerosis,
tendency to spasms of the coronary vessels,
hypersensitivity to phenylephrine.
pharmachologic effect
Adrenomimetic. It has a direct stimulating effect mainly on ?-adrenergic receptors.
With systemic use, it causes narrowing of arterioles, increases OPSS and blood pressure. Cardiac output does not change or decreases, which is associated with reflex bradycardia (increased vagus tone) in response to hypertension. Phenylephrine does not raise blood pressure as sharply as norepinephrine and epinephrine, but it lasts longer. This, apparently, is due to the fact that phenylephrine is more stable and is not destroyed under the influence of COMT.
When applied topically, phenylephrine has a pronounced vasoconstrictor effect, causes mydriasis, and can lower intraocular pressure in open-angle glaucoma.
In average therapeutic doses, it practically does not affect the central nervous system.
Side effect
From the side of the cardiovascular system: possible undesirable prolonged increase in blood pressure, tachycardia or reflex bradycardia.
Local reactions: irritating effect on mucous membranes is possible.
Application during pregnancy and lactation
There have been no adequate and strictly controlled clinical studies of the safety of phenylephrine during pregnancy and lactation.
special instructions
The use of phenylephrine should be avoided in patients with severe hyperthyroidism.
Use with caution in coronary artery disease.
When applied topically after absorption through the mucous membrane, phenylephrine can cause systemic effects. In this regard, the use of phenylephrine in the form of 10% eye drops in infants and elderly patients should be avoided.
Drug interactions
When using phenylephrine against the background of general anesthesia caused by halothane or cyclopropane, ventricular fibrillation may develop.
With simultaneous use with MAO inhibitors, there is a potentiation of the effects of phenylephrine (including when applied topically).
Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics reduce the vasoconstrictor effect of phenylephrine.
Guanethidine enhances the mydriatic effect of phenylephrine (with systemic absorption).
Oxytocin, ergot alkaloids, tricyclic antidepressants, furazolidone, procarbazine, selegiline, sympathomimetics increase the pressor effect, and the latter also increase arrhythmogenicity.
With simultaneous use of beta-blockers reduce cardiac stimulating activity; against the background of reserpine, arterial hypertension is possible (due to the depletion of reserves of catecholamines in adrenergic neurons, sensitivity to sympathomimetics increases).